The blood and bone marrow transplant programme at Nebraska Medicine in Omaha, performing adult and paediatric stem cell transplants for blood cancers and other disorders since 1983.
This is the blood and bone marrow transplant programme of Nebraska Medicine, based at the Fred and Pamela Buffett Cancer Center on the Nebraska Medical Center campus at 505 South 45th Street, Omaha. It is a hospital programme within an academic cancer centre rather than a private clinic. The site states that the programme has averaged around 150 transplants a year since 1983 and describes itself as one of the busiest adult and paediatric stem cell transplant programmes in the world.
The transplant types described are autologous transplant, using the patient's own bone marrow or peripheral blood stem cells collected before chemotherapy or radiotherapy; allogeneic transplant, using cells from a matched donor who may be a relative or an unrelated donor identified through the National Marrow Donor Program, including reduced-intensity and half-matched (haploidentical) approaches; syngeneic transplant, using cells from an identical twin; and CAR T-cell therapy, in which immune cells are modified in a laboratory.
This is established cell therapy for serious disease within a hospital cancer service, and it should be distinguished from the commercial stem cell injections offered by many of the clinics in this directory. The conditions treated are leukaemia, lymphoma, myeloma, paediatric solid tumours including neuroblastoma and certain brain tumours, severe combined immunodeficiency, metabolic diseases, and non-malignant blood disorders such as sickle cell anaemia.
The programme lists accreditation by the Foundation for the Accreditation of Cellular Therapy, membership of the Pediatric Blood and Marrow Transplant Consortium, and status as a National Cancer Institute designated cancer centre and a National Comprehensive Cancer Network member. No individual physicians are named on the page reviewed, and no cost or insurance information is given; treatment of this kind is normally covered by health insurance for eligible diagnoses, but that would need confirming with the programme and the insurer.
The programme treats serious blood, immune and childhood cancer conditions.
The programme uses both the patient's own cells and donor cells, as transplant medicine requires, and the page is explicit about which is which.
No individual clinicians are named on the page reviewed; the programme is staffed by a hospital haematology and transplant team.
The programme is based at the Fred and Pamela Buffett Cancer Center at the Nebraska Medical Center, 505 South 45th Street, Omaha, Nebraska 68105 — a purpose-built academic cancer hospital with inpatient transplant facilities. The page describes a long-standing, high-volume programme with cellular therapy accreditation and both adult and paediatric services.
The page reviewed gives no cost or insurance information. Transplantation for eligible cancer and blood disorder diagnoses is normally covered by health insurance in the United States, and this is a hospital programme rather than a self-pay clinic, but cover would need to be confirmed with the programme and the insurer.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.